Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inebilizumab - Horizon Therapeutics plc

Next Previous
X
Search
Drug Profile

Inebilizumab - Horizon Therapeutics plc

Alternative Names: 16C4-aFuc; A-fucosylated anti-CD19 antibody; Anti-CD19 MAb-Horizon Therapeutics plc; Inebilizumab-cdon; MEDI 551; MT-0551; UPLIZNA; VIB-0551

Latest Information Update: 22 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University
  • Developer Horizon Therapeutics plc; Jiangsu Hansoh Pharmaceutical; MedImmune; Mitsubishi Tanabe Pharma Corporation
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuromyelitis optica; Scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuromyelitis optica
  • Phase III Immunoglobulin G4-related disease; Myasthenia gravis; Systemic scleroderma
  • No development reported Renal transplant rejection
  • Discontinued B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Multiple sclerosis

Most Recent Events

  • 14 Nov 2024 Efficacy and adverse event data from the phase III MITIGATE trial in Immunoglobulin G4 related disease released by Amgen
  • 15 Oct 2024 efficacy data from a phase III trial in Myasthenia gravis released by Amgen
  • 19 Sep 2024 Amgen initiates expanded access programme for Immunoglobulin G4 related disease (In children, In adults, In the elderly) (NCT06590051)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top